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ABSTRACT 
Background: Even though the association between thyroid dysfunction and anemia is 
commonly described, we do not know whether it is clinically relevant. We set out to 
quantify the association of thyroid dysfunction on hemoglobin (Hb) concentration and risk 
of anemia, and conducted a systematic review (MEDLINE & EMBASE, from inception until 
May 15th, 2017) to interpret our findings in context. 
Methods: We included participants from the EPIC-Norfolk cohort with available baseline 
thyroid-stimulating hormone (TSH), free thyroxine (fT4), and Hb. We defined euthyroidism 
as TSH 0.45-4.49mIU/l (reference category), hypothyroidism as TSH ≥4.50 mIU/l 
(subclinical (SHypo) with normal fT4 or overt (OHypo) with low fT4), and hyperthyroidism 
as TSH ≤0.44 mIU/l (subclinical (SHyper) with normal fT4 or overt (OHyper) with elevated 
fT4). Anemia was defined as Hb <12 g/dl in women and Hb <13 g/dl in men. In the cross-
sectional analyses, we used multiple linear regression to compare Hb across TSH 
categories. In the prospective analysis, we excluded participants with OHypo/OHyper at 
baseline as we assumed they were treated for overt thyroid disease. We used a covariance 
model (ANCOVA) to determine change in Hb concentration from baseline to last follow-up, 
and multivariable Cox regression to analyze anemia risk.  
Results: In the cross-sectional population (n=12,337), the adjusted Hb was 0.22 g/dl lower 
(95% confidence interval [95%CI] 0.07 to 0.38) in OHypo than in euthyroids, and 0.08 g/dl 
lower (95%CI -0.23 to 0.38) in OHyper. In the prospective analysis, 460/7031 participants 
developed anemia over a median follow-up of 4.7 years. The adjusted mean Hb change 
over time was -0.04 g/dl in SHypo (95%CI -0.14 to 0.06) and 0.05 g/dl in SHyper (95%CI -
0.10 to 0.20). The adjusted hazard ratio for anemia was 0.99 (95%CI 0.67-1.48) in SHypo, 
and 0.52 (95%CI 0.23-1.16) in SHyper. Our systematic review returned no other 
prospective studies on this association, but cross-sectional and case-control studies 
showed comparable results. 
Conclusion: In this first prospective population-based cohort, subclinical thyroid 
dysfunction was not associated with a change in Hb concentration during follow-up and 
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was not an independent risk factor for developing anemia; variations in Hb concentration 
in patients with overt thyroid dysfunction were not clinically relevant. 
Key Words: Anemia, Thyroid Dysfuntion, Thyroid Stimulating Hormone, Hemoglobin, 
Clinical Relevance, Prospective Population-based Cohort 
Funding source: This project was supported by grants from the Swiss National Science 
Foundation (SNSF 320030-150025 and 320030-172676 to Prof N Rodondi; P3SMP3-
155318, PZ00P3-167826 to Dr T-H Collet).  
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Introduction 
A causal relationship between overt hypothyroidism (OHypo) / overt hyperthyroidism 
(OHyper) and anemia has been postulated for decades (1-3). Researchers have suggested 
several pathophysiological mechanisms (4, 5). Hyperthyroidism enhances erythropoiesis, 
but it also raises the basal metabolic rate. The latter may increase plasma volume (3), 
counteracting the effect of erythropoiesis and lowering hemoglobin (Hb) concentration, 
ultimately causing anemia. In hypothyroidism, a drop in basal metabolic rate and a 
decrease in cellular oxygen consumption may reduce erythropoietin secretion, which 
would also lower Hb concentration and, ultimately, cause either normocytic, microcytic, or 
macrocytic anemia, depending on comorbidities (1, 6). Although several studies explored 
the pathophysiologic link between thyroid dysfunction and erythroid development (5, 7), 
we do not know whether, or to what extent, thyroid dysfunction alone (in the absence of 
comorbidities) affects Hb concentration, or if the effect would be clinically relevant in large 
epidemiological studies. 
Limited data exist on the association between thyroid dysfunction and anemia. Case-series 
from the 1960s and 1970s had no control group (1, 8, 9). More recent cross-sectional 
studies did not consider potentially relevant confounders, such as renal function or C-
reactive protein (10, 11), and included few patients with hypothyroidism (10-13). Only two 
studies reported on hyperthyroidism and anemia (11, 14), and no prospective study 
assessed the incidence of anemia in subclinical thyroid dysfunction. 
Therefore, we aimed to quantify the effect of thyroid dysfunction on Hb concentration in a 
large population-based cohort, and assess its association with anemia. We did both a 
cross-sectional and a prospective analysis, and completed a systematic review. 
Material and Methods 
We report the study in accordance with the STrengthening the Reporting of OBservational 
studies in Epidemiology (STROBE) statement (15). We report the results of our systematic 
review of observational studies according to the Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) statement (16).  For our systematic review, one author (CF) 
searched OVID-MEDLINE and EMBASE (from inception to May 15th, 2017) for studies that 
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examined the link between thyroid function and anemia, and checked bibliographies of 
included articles. We included studies with results on both Hb/anemia and thyroid 
dysfunction in adult, non-pregnant participants, and excluded those without an euthyroid 
control group. The appendix contains details of our search strategy. For quality 
assessment, we rated each included study using the Newcastle-Ottawa Quality Assessment 
Scale (NOS) for case-control studies or an adapted version for cross-sectional studies.  
Setting and study population 
We used data from the European Prospective Investigation of Cancer (EPIC) Norfolk 
cohort, a prospective observational study of 25,639 women and men, aged 40-79 at 
enrolment (17, 18). Everyone in this age range registered in the general practitioner 
databases of Norwich, UK, and surroundings, was invited from 1993 to 1997. The Norwich 
local research ethics committee (United Kingdom) approved the study, and all participants 
gave written informed consent. We included participants in our cross-sectional analysis if 
measurements of their baseline thyroid-stimulating hormone (TSH), free thyroxine (fT4), 
and Hb were available at study entry. We excluded those who self-reported thyroid 
dysfunction, because we assumed that most would already be in treatment for thyroid 
dysfunction. For the prospective analysis, we excluded (i) participants with anemia at 
baseline (as anemia would be the prospective outcome), (ii) those with no available Hb 
measurments during follow-up, (iii) and those diagnosed with overt thyroid dysfunction at 
baseline, because we assumed they received thyroid therapy after diagnosis. Descriptive 
results on thyroid dysfunction and anemia were already reported in this population, in a 
cross-sectional explanatory analysis without multivariable models to account for 
confounders through a rapid communication (19). In this study, we report on new 
multivariable analyses and new prospective analyses that were not available in the 
previous rapid communication. 
Definition of main outcomes, exposures, and potential confounders 
The primary outcome of the cross-sectional analysis was Hb concentration. The secondary 
outcome was anemia, defined as Hb <12 g/dl for women and <13 g/dl for men (binary 
variable) (20). The main exposure variable was thyroid dysfunction, classified by TSH 
categories. To make our study easier to compare with others, guided by expert reviews 
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(21, 22), we defined hypothyroidism as TSH ≥4.50 mIU/l, either subclinical (SHypo), with 
normal free thyroxine (fT4) or overt (OHypo) with fT4 below the reference range (23). We 
defined hyperthyroidism as TSH ≤0.44 mIU/l, either subclinical (SHyper) with normal fT4, 
or overt (OHyper) with fT4 above the reference range (23). The reference category was 
euthyroidism (TSH 0.45-4.49 mIU/l and fT4 within reference range 9.00-20.00 pmol/l) (23). 
A secondary exposure variable was fT4. In our prospective analysis, the primary outcome 
was the difference in Hb concentration between the last available follow-up Hb and 
baseline Hb (numerical variable, g/dl). The secondary outcome was incident anemia. The 
main exposure variable was thyroid dysfunction, classified by TSH categories (i.e. SHypo, 
SHyper, euthyroidism as reference). The secondary exposure variable was fT4 (categorized 
in quintiles), as in the cross-sectional analysis. We measured the following potential 
confounders at baseline: age (continuous variable); sex; body mass index (continuous 
variable); smoking (never, past, present); self-reported history of myocardial infarction, 
diabetes, stroke (binary variables; yes/no); ferritin (continuous variable); estimated 
glomerular filtration rate (eGFR, continuous variable); C-reactive Protein (CRP, continuous 
variable); and mean corpuscular volume (MCV, continuous variable; as a surrogate 
parameter for B12/folic acid deficiency, since these measurements were unavailable in the 
EPIC-Norfolk study). 
Statistical analyses 
In the cross-sectional analysis, we used multiple linear regression to compare Hb across 
TSH categories (OHypo, SHypo, SHyper, OHyper, euthyroidism as reference category). We 
also used multiple linear regression to compare Hb concentration across fT4 quintiles (mid 
quintile as reference). To explore the association between thyroid dysfunction and anemia, 
we used logistic regression to compare the odds of anemia across TSH categories and fT4 
quintiles. For all analyses, we used three models: unadjusted; age- and sex-adjusted; and 
fully adjusted considering the confounders we already mentioned. We based our inclusion 
of confounders on a likelihood ratio test (p<0.1 as cut-off) that told us which confounders 
were most likely to confound the association between exposure and outcome in bivariable 
models. 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ité
 d
e 
La
us
an
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
11
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 7 of 67 
 
 
 
7 
Th
yr
oi
d 
Th
yr
oi
d 
Dy
sf
un
ct
io
n 
an
d 
An
em
ia
: A
 P
ro
sp
ec
tiv
e 
Co
ho
rt
 S
tu
dy
 a
nd
 a
 S
ys
te
m
at
ic 
Re
vi
ew
 (D
OI
: 1
0.
10
89
/t
hy
.2
01
7.
04
80
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
In the prospective analysis, we analyzed a covariance model (ANCOVA) to determine 
change in Hb concentration from baseline to last follow-up, taking into account baseline 
Hb concentrations (24). We presented results as difference in mean change of Hb between 
SHypo/SHyper and euthyroidism (24, 25). We then used multivariable Cox regression 
models to compare the incidence of anemia in SHypo/SHyper to euthyroidism and, in a 
further analysis, the incidence of anemia across fT4 quintiles. Again, we used three 
models: unadjusted; age- and sex-adjusted; and fully adjusted, similar to the cross-
sectional analyses described above. 
We used multiple imputation (30 imputations) to complete missing values in potentially 
relevant confounders in cross-sectional and prospective analyses (for the cross-sectional 
population: body mass index 24 (0.19%) missing, smoking status 93 (0.75%) missing, 
ferritin 3,851 (31.2%) missing, eGFR 3,266 (26.5%) missing, and CRP 3,311 (26.8%) missing; 
for the prospective population: body mass index 11 (0.16%) missing, smoking status 44 
(0.63%) missing, ferritin 2068 (29.4%) missing, eGFR 1835 (26.1%) missing, and CRP 1855 
(26.4%) missing), and further assessed and ruled out that iron status modifies the 
association between thyroid dysfunction and Hb.(26) Finally, we conducted sensitivity 
analyses that used the original, unimputed data. Tests were two-sided, at a 0.05 level of 
significance. We used STATA, release 14.2 (StataCorp LP, College Station, Texas 77845 
USA) for all our analyses. 
Results 
After we excluded participants with self-reported thyroid disease (n=635), we included 
12,337 participants in the cross-sectional analysis. Of these, 976 (7.9%) had anemia, most 
(11,174, [90.6%]) were euthyroid; 644 (5.2%) had SHypo, 199 (1.6%) OHypo, 270 (2.2%) 
SHyper, and 50 (0.4%) had OHyper (Table 1). We observed no relevant differences in Hb 
concentration among TSH categories. In multivariable analyses, Hb was 0.22 g/dl (95%CI 
0.07 to 0.38) lower in OHypo than in euthyroidism, and 0.08 g/dl (95%CI -0.23 to 0.38) 
lower in OHyper (Table 2). The adjusted odds ratio (OR) for anemia was 1.96 (95%CI 1.29-
2.98) in OHypo, 2.18 (95%CI 0.98-4.87) in OHyper, but we found no association in 
SHypo/SHyper (eTable 2). 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ité
 d
e 
La
us
an
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
11
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 8 of 67 
 
 
 
8 
Th
yr
oi
d 
Th
yr
oi
d 
Dy
sf
un
ct
io
n 
an
d 
An
em
ia
: A
 P
ro
sp
ec
tiv
e 
Co
ho
rt
 S
tu
dy
 a
nd
 a
 S
ys
te
m
at
ic 
Re
vi
ew
 (D
OI
: 1
0.
10
89
/t
hy
.2
01
7.
04
80
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
For the prospective analysis, we excluded participants with anemia at baseline (n=976), 
overt thyroid dysfunction at baseline (n=212), and missing follow-up data on hemoglobin 
(n=4118). The latter group was similar to the included prospective study population with 
regard to thyroid (dys-)function, age, sex, and baseline Hb concentration. We followed 
7031 participants (Table 3) over 55,733 person years (median 4.7 years). Anemia 
developed during follow-up in 26 of 368 (7.1%) participants with SHypo, 428 of 6496 
(6.6%) participants with euthyroidism, and 6 of 167 (4.0%) participants with SHyper. In the 
ANCOVA analysis, when we compared SHypo/SHyper with euthyroidism, we found no 
difference in adjusted mean Hb change (SHypo: -0.04 g/dl, 95%CI -0.14 to 0.06; SHyper: 
0.05 g/dl, 95%CI -0.10 to 0.20, Table 4). When we compared SHypo and SHyper to 
euthyroidism, the adjusted hazard ratio for anemia was 0.99 for SHypo (95%CI 0.67-1.48) 
and 0.52 for SHyper (95%CI 0.23-1.16) (Table 5).  
All results (from cross-sectional and prospective analyses) were similar in our sensitivity 
analyses, which used the original unimputed data (eTable 1-4). Results for fT4 as exposure 
variable in both the cross-sectional and the prospective analyses, with imputed and 
original data, yielded no relevant associations (eTable 1-4). 
Our literature search (see the Appendix for detailed search strategy) identified 2721 
articles in OVID-MEDLINE and EMBASE. After excluding duplicates, we used title and 
abstract to screen 2692 articles. We excluded 2661 papers and assessed 31 full-text 
articles (eFigure 1). A manual check of article bibliographies revealed 14 more potentially 
eligible studies. Of these 45 candidates, 37 articles were excluded after full-text evaluation 
(eTable 6), and eight articles finally met our inclusion criteria (eTable 5); four were cross-
sectional studies,(10, 12-14) four were case-control studies,(11, 27-29) and none had a 
prospective design. 
Two of the four cross-sectional studies were population-based and of fair methodological 
quality,  scoring five out of seven points in the Newcastle-Ottawa Quality Assessment Scale 
(eTable 7) (10, 13). Yet, both studies were small, included fewer than 100 patients with 
SHypo and/or OHypo, excluded participants with hyperthyroidism (both SHyper and 
OHyper), and did not report significant differences in Hb concentrations across exposure 
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categories. After adjusting for relevant confounders, Bremner et al. found Hb 
concentration was 13.7 g/dl in participants with SHypo, and 14.2 g/dl (p=0.29) in 
participants with euthyroidism (13). Den Elzen et al. found Hb concentration was 12.8 g/dl 
in participants aged >85y with OHypo, 13.1 g/dl in those with SHypo, and 13.0 g/dl in those 
with euthyroidism (10). In a retrospective analysis of 6534 consecutive female patients 
referred to a university hospital, Lippi et al. found similar Hb concentrations among 
participants with hypothyroidism (Hb 13.2 g/dl), euthyroidism (13.3 g/dl), and 
hyperthyroidism (13.1 g/dl) (14), but used uncommon definitions for thyroid dysfunction 
(hypothyroidism TSH >2.5 mU/l; euthyroidism TSH 0.2-2.5 mU/l; hyperthyroidism TSH <0.2 
mU/l) (14); these could have biased the results towards the null effect (23). Regarding 
methodological quality, the NOS score was moderate with three out of seven points 
(eTable 7). In their cross-sectional analysis, however, Vitale et al., reported higher 
prevalence of hypothyroidism in hospitalized patients aged >65 years with anemia (20%) 
than in control patients without anemia (9.9%; p=0.01) (12). In this study, Hb 
concentrations increased an average of 1.6 g/dl in nine patients with hypothyroidism and 
anemia after they were treated with thyroxine (12). It was not clear, however, how the 
nine out of 21 patients with anemia, hypothyroidism, and no other potential cause of 
anemia were selected for thyroxine treatment. Overall, the methodological quality was 
moderate with an NOS score of three out ouf seven points (eTable 7). We included four 
case-control studies in our systematic review (7, 11, 27, 29). Each reported slightly more 
pronounced differences in Hb concentrations across the categories of thyroid dysfunction. 
Mean Hb concentrations among euthyroid participants ranged from 12.8 to 14.7 g/dl; 
corresponding values were 10.8 to 12.7 g/dl in SHypo, and 10.7 to 13.2 g/dl in OHypo. 
These studies included participants with more severe thyroid dysfunction (e.g., in 
Jafarzadeh et al., the 50 participants with OHypo had a mean TSH of 136.5mU/l (11)). They 
were of low methodological quality, scoring two out of 10 points in the adapted NOS 
(eTable 8). These methodological limitations make it hard to determine if the slightly more 
pronounced differences in Hb concentrations were real (because thyroid dysfunction was 
more severe) or spurious (a product of bias). 
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Only two of the eight included studies considered hyperthyroidism (11, 14). Both were 
negative. In the study by Lippi et al., Hb was 13.1 g/dl among hyperthyroid participants 
(subclinical and overt) and 13.3 g/dl among euthyroid participants(14); in the study by 
Jafarzadeh et al., Hb was 13.8 g/dl in OHyper and 14.0 g/dl in euthyroidism (11). 
Discussion 
In this first prospective population-based cohort, subclinical thyroid dysfunction was not 
associated with a change in Hb concentration during follow-up and was not an 
independent risk factor for developing anemia. OHypo and OHyper were associated with 
anemia in the cross-sectional analyses. This is congruent with pathophysiologic findings 
that Thyroid Hormone Receptor alpha (TRα) is expressed by hematopoietic and erythroid 
progenitors and regulates erythropoiesis (4, 5, 7). However, the differences in mean Hb 
concentrations between OHypo/OHyper participants and euthyroidism were not clinically 
relevant. In the cross-sectional and prospective analysis, we found no relevant association 
between fT4 and anemia. Our systematic review did not identify other prospective cohort 
studies on the association between thyroid dysfunction and anemia/hemoglobin, and 
results from the included cross-sectional and case-control studies were comparable to the 
results of our cohort study. 
Our study has limitations. First, we only measured thyroid hormones once, at baseline; we 
might have misclassified patients who had either transient subclinical thyroid dysfunction, 
who developed overt thyroid over time, or who reverted to euthyroidism over time. This 
single measurement may have biased our prospective results towards the null-effect, but 
the same is true of most large prospective cohorts that actually found associations with 
other outcomes like coronary heart disease(23) and fractures (30). Second, we had no 
measurements for vitamin B12 and folic acid. Despite this, the daily intake of participants 
included the current recommended dose of both (vitamin B12 200-350 μg, folic acid 2-14 
mg) (31-33) and we adjusted for MCV (a surrogate parameter for B12/folic acid 
deficiency). Third, although the EPIC-Norfolk cohort is population-based, we could analyze 
data from only 12,337 (48.1%) of the 25,639 eligible participants because we had no 
thyroid function or hemoglobin measurements for some participants. We cannot be sure 
our study population represents the whole potentially eligible population. Fourth, in our 
prospective analyses, healthy participants could have been more likely to be available for 
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follow-up examinations than sick participants (healthy cohort effect). If sick participants 
were both more anemic and more likely to suffer from thyroid dysfunction, then we may 
have underestimated the association between subclinical thyroid dysfunction and anemia. 
However, the consistent results between our cross-sectional and the prospective analyses 
suggest that healthy cohort effect was not substantial. Fifth, we could not exclude 
participants who developed conditions during follow-up that could affect Hb (e.g. 
hematological malignancies, chronic diseases), as this information was not available. As 
hematological malignancies are not associated with thyroid dysfunction, they should not 
be an important confounder. Chronic diseases could be associated with thyroid 
dysfunction, at least with subclinical hypothyroidism. In our prospective analyses, we may 
have attributed incident anemia cases to thyroid dysfunction when, in fact, anemia 
occurred due to chronic diseases. In this case, however, we would have overestimated the 
association between thyroid dysfunction and anemia, while we did not find significant 
large associations. Finally, the observational design of our study precluded causal 
inference. 
Our study also has several strengths. It is the largest population-based study to examine 
the association between thyroid dysfunction and Hb concentration/anemia, and to 
consider both hypo- and hyperthyroidism. It is the first prospective cohort study on the 
topic to have a long follow-up period (almost 5 years). Our results are consistent between 
our cross-sectional, prospective, and sensitivity analyses, and we could adjust for most 
potentially relevant confounders. Our findings are strengthened by the systematic review 
we conducted, since it enabled us to interpret our results in the context of all available 
literature on the topic. 
Conclusion 
In this first prospective population-based cohort, subclinical thyroid dysfunction was not 
associated with a change in Hb concentration during follow-up and was not an 
independent risk factor for developing anemia; variations in Hb concentration in patients 
with overt thyroid dysfunction were not clinically relevant. 
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Table 1: Baseline characteristics of the cross-sectional study population (N=12,337) 
 OHypo SHypo Euthyroidism SHyper OHyper 
p-
value° 
Participants 199 (1.6) 644 (5.2) 11,174 (90.6) 270 (2.2) 50 (0.4)  
Demographics       
Age [y] 
60.4 
(9.2) 
60.7 
(9.0) 
58.6 (9.5) 
59.1 
(10.0) 
62.3 (9.9) <0.001
Female 
149 
(74.9) 
444 
(68.9) 
5,785 (51.8) 
151 
(55.9) 
28 (56.0) <0.001
Laboratory 
parameters 
      
TSH [mIU/l] 
25.66 
(31.5) 
7.78 
(16.6) 
1.84 (0.8) 
0.27 
(0.1) 
0.16 (0.2) <0.001
Free T4 [pmol/l] 7.3 (1.6) 
11.2 
(1.5) 
12.4 (1.8) 
14.0 
(2.2) 
35.5 (19.6) <0.001
Anemia* 29 (14.6) 55 (8.5) 866 (7.8) 18 (6.7) 8 (16.0) 0.001 
Hemoglobin 
[g/dl] 
13.4 
(1.2) 
13.6 
(1.4) 
13.9 (1.3) 
13.8 
(1.3) 
13.7 (1.6) <0.001
MCV [fl] 
89.4 
(4.5) 
88.9 
(4.5) 
89.3 (4.4) 
89.2 
(4.5) 
88.5 (4.3) 0.196 
Ferritin [ng/ml] 
78.5 
(71.9) 
79.2 
(63.6) 
89.6 (75.2) 
84.2 
(77.2) 
95.6 
(101.4) 
0.019 
CRP [mg/l] 3.6 (6.5) 
4.2 
(12.0) 
3.0 (5.6) 
3.9 
(11.2) 
3.8 (6.1) <0.001
eGFR [ml/min] 
70.9 
(20.0) 
72.5 
(19.5) 
77.7 (24.9) 
82.9 
(35.7) 
74.3 (25.9) <0.001
BMI categories       
<25.0 kg/m2 66 (33.2) 
232 
(36.0) 
4,432 (39.7) 
122 
(45.2) 
20 (40.0) overall
0.046 
25.0-29.9 kg/m2 90 (45.2) 292 5,099 (45.6) 112 23 (46.0) 
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(45.3) (41.5) 
≥30.0 kg/m2 42 (21.1) 
118 
(18.3) 
1,623 (14.5) 35 (13.0) 7 (14.0) 
Smoking status       
Never 88 (44.2) 
342 
(53.1) 
5,055 (45.2) 
107 
(39.6) 
25 (50.0) 
overall
<0.001 Past 89 (44.7) 
253 
(39.3) 
4,693 (42.0) 
122 
(45.2) 
20 (40.0) 
Present 19 (9.6) 41 (6.4) 1,348 (12.1) 38 (14.1) 4 (8.0) 
Medical History       
Myocardial 
Infarction 
4 (2.0) 18 (2.8) 342 (3.1) 3 (1.1) 0 0.216 
Stroke 0 16 (2.5) 134 (1.2) 5 (2.2) 2 (4.0) 0.004 
Diabetes 
mellitus 
2 (1.0) 13 (2.0) 241 (2.2) 4 (1.5) 3 (6.0) 0.247 
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Table 2: Multiple linear regression: hemoglobin concentrations [g/dl] compared across 
thyroid dysfunction categories in the cross-sectional study population (N=12,337)  
 OHypo SHypo Euthyroidism SHyper OHyper
Participants (%) 199 (1.6) 644 (5.2) 11,174 (90.6) 270 (2.2) 50 (0.4)
Crude analysis 
-0.52 
(-0.71 to -
0.33) 
-0.29 
(-0.40 to -
0.18) 
Ref. 
-0.10 
(-0.26 to 
0.06) 
-0.16 
(-0.53 to 
0.21) 
Age- and sex-
adjusted analysis 
-0.19 
(-0.35 to -
0.03) 
-0.05 
(-0.14 to 
0.04) 
Ref. 
-0.04 
(-0.18 to 
0.10) 
-0.11 
(-0.43 to 
0.20) 
Multivariable° 
analysis 
with imputed§ 
data 
-0.22 
(-0.38 to -
0.07) 
-0.03 
(-0.11 to 
0.06) 
Ref. 
-0.02 
(-0.15 to 
0.11) 
-0.08 
(-0.38 to 
0.23) 
Multivariable° 
analysis  
with original+ 
data 
-0.28 
(-0.45 to -
0.11) 
-0.04 
(-0.14 to 
0.05) 
Ref. 
-0.01 
(-0.17 to 
0.16) 
-0.42 
(-0.82 to -
0.03) 
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Table 3: Baseline characteristics of the prospective study population (N=7,031)* 
 SHypo Euthyroidism SHyper p-value° 
Participants 368 (5.2) 6,496 (92.4) 167 (2.4)  
Demographics  
Age [y] 60.1 (8.8) 58.2 (9.0) 57.5 (10.0) <0.001 
Female 248 (67.4) 3,302 (50.8) 95 (56.9) <0.001 
Laboratory 
parameters 
    
TSH [mIU/l] 7.1 (4.5) 1.8 (0.9) 0.27 (0.13) <0.001 
Free T4 [pmol/l] 11.2 (1.6) 12.4 (1.7) 13.9 (2.2) <0.001 
Hemoglobin [g/dl] 13.8 (1.1) 14.0 (1.2) 14.0 (1.3) <0.001 
MCV [fl] 89.0 (4.1) 89.5 (3.8) 89.6 (3.7) 0.057 
Ferritin [ng/ml] 77.1 (59.4) 89.9 (74.8) 89.5 (84.7) 0.021 
CRP [mg/l] 3.6 (11.8) 2.6 (4.7) 3.9 (13.4) 0.001 
eGFR [ml/min] 72.2 (18.4) 77.7 (24.0) 82.1 (36.9) <0.001 
BMI categories  
<25.0 kg/m2 143 (39.0) 2,715 (41.9) 80 (47.9) 
overall 
0.288 
25.0-29.9 kg/m2 163 (44.4) 2,926 (45.1) 66 (39.5) 
≥30.0 kg/m2 61 (16.6) 845 (13.0) 21  (12.6)
Smoking status     
Never 205 (56.3) 3,114 (48.2) 70 (41.9)  
Past 136 (37.4) 2,681 (41.5) 75 (44.9) 
overall 
0.008 
Present 23 (6.3) 661 (10.2) 22 (13.2)  
Medical History  
Myocardial 
Infarction 
9 (2.5) 155 (2.4) 1 (0.6) 0.319 
Stroke 9 (2.5) 58 (0.9) 1 (0.6) 0.011 
Diabetes mellitus 7 (1.9) 112 (1.7) 3 (1.8) 0.966 
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Table 4: Changes in hemoglobin concentration [g/dl] compared across thyroid 
dysfunction categories in the prospective cohort (N=7,031)* 
 SHypo Euthyroidism SHyper 
Participants (%) 368 (5.2%) 6496 (92.4%) 167 (2.4%)
Baseline hemoglobin, mean (SD) 13.8 (1.1) 14.0 (1.2) 14.0 (1.3) 
Follow-up hemoglobin, mean (SD) 13.8 (1.2) 14.1 (1.3) 14.1 (1.1) 
Difference in adjusted° mean 
change of hemoglobin (95%CI), 
imputed§ dataset 
-0.04
(-0.14 to 
0.06) 
Ref. 
0.05 
(-0.10 to 
0.20) 
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Table 5: Hazard ratio for anemia: subclinical thyroid dysfunction compared to euthyroidism 
in the prospective study population (N=7,031)* 
 SHypo Euthyroidism SHyper 
Anemia N (%) 26 (7.1) 428 (6.6) 6 (3.6) 
HR for anemia 
(95%CI) 
   
Crude analysis 
0.94
(0.63-1.39) 
Ref. 
0.52 
(0.23-1.16) 
Age- and sex-
adjusted analysis 
1.00 
(0.67-1.49) 
Ref. 
0.51 
(0.23-1.13) 
Multivariable° 
analysis with 
imputed§ data  
0.99 
(0.67-1.48) 
Ref. 
0.52 
(0.23-1.16) 
Multivariable° 
analysis with 
original data+ 
0.86 
(0.53-1.40) 
Ref. 
0.69 
(0.29-1.68) 
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Table 1: Results are presented as: number (percentage) for categorical variables, mean 
(standard deviation) for continuous variables 
°p-values derived from one-way analysis of variance models in case of 
continuous variables and from χ2 tests in case of categorical variables 
*Definition of anemia: Hb<12g/dl for women, Hb<13g/dl for men 
Missing data: BMI (24 [0.19%]), smoking status (93 [0.75%]), ferritin (3,851 
[31.2%]), eGFR (3,266 [26.5%]), and CRP (3,311 [26.8%]) 
Abbreviations: N, number; OHypo, overt hypothyroidism; SHypo, subclinical 
hypothyroidism; SHyper, subclinical hyperthyroidism; OHyper, overt hyperthyroidism; y, 
years; TSH, thyroid stimulating hormone; T4, thyroxine; MCV, mean corpuscular volume; 
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; BMI, body mass index  
 
Table 2: In brackets are 95% confidence intervals, if not otherwise stated 
°Adjustments: age, sex, BMI, smoking status, myocardial infarction, diabetes mellitus, 
stroke, ferritin, eGFR, CRP, MCV 
§Imputation for BMI (24 [0.19%] missing), smoking status (93 [0.75%] missing), ferritin 
(3,851 [31.2%] missing), eGFR 
(3,266 [26.5%] missing), and CRP (3,311 [26.8%] missing). All other variables were complete 
+N = 8,275 
Abbreviations: N, number; OHypo, overt hypothyroidism; SHypo, subclinical 
hypothyroidism; SHyper, subclinical hyperthyroidism; OHyper, overt hyperthyroidism; Ref., 
reference; BMI, body mass index; eGFR, estimated glomerular filtration rate; CRP, C-reactive 
protein; MCV, mean corpuscular volume 
 
Table 3: Results are presented as: number (percentage) for categorical variables, mean 
(standard deviation) for continuous variables 
*We included only participants without anemia or overt thyroid dysfunction at baseline, and 
with available hemoglobin assessment during follow-up 
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°p-values derived from one-way analysis of variance models in case of continuous variables 
and from χ2 tests in case of categorical variables 
Missing data: BMI (11 [0.16%]), smoking status (44 [0.63%]), ferritin (2,068 
[29.4%]), eGFR (1,835 [26.1%]), and CRP (1,855 [26.4%]) 
Abbreviations: N, number; SHypo, subclinical hypothyroidism; SHyper, subclinical 
hyperthyroidism; y, years; TSH, thyroid stimulating hormone; T4, thyroxine; MCV, mean 
corpuscular volume; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; 
BMI, body mass index  
 
Table 4:  
*We included only participants without anemia or overt thyroid dysfunction at baseline, and 
with available hemoglobin assessment during follow-up 
°Adjustments: baseline hemoglobin, length of follow-up in years, age, sex, BMI, smoking 
status, myocardial infarction, diabetes mellitus, stroke, ferritin, eGFR, CRP, MCV 
§Imputation for BMI (11 [0.16%] missing), smoking status (44 [0.63%] missing), ferritin 
(3,851 [31.2%] missing), eGFR (3,266 [26.5%] missing), and CRP (3,311 [26.8%] missing). All 
other variables were complete 
Abbreviations: N, number; SHypo, subclinical hypothyroidism; SHyper, 
subclinical hyperthyroidism; SD, standard deviation; CI, confidence interval; Ref., 
reference; BMI, body mass index; eGFR, estimated glomerular filtration rate; 
CRP, C-reactive protein; MCV, mean corpuscular volume  
 
Table 5: In brackets are 95% confidence intervals, if not otherwise stated  
*We included only participants without anemia or overt thyroid dysfunction at baseline, and 
with available hemoglobin assessment during follow-up 
°Adjustments: age, sex, BMI, diabetes mellitus, ferritin, MCV  
§Imputation for BMI (11 [0.16%] missing), smoking status (44 [0.63%] missing), 
ferritin (3,851 [31.2%] missing), eGFR (3,266 [26.5%] missing), and CRP (3,311 
[26.8%] missing). All other variables were complete 
+N = 4,955 
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Abbreviations: N, number; SHypo, subclinical hypothyroidism; SHyper, subclinical 
hyperthyroidism; HR, hazard ratio; CI, confidence interval; Ref., reference; BMI, body mass 
index; MCV, mean corpuscular volume; eGFR, estimated glomerular filtration rate; CRP, C-
reactive protein 
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Appendix 
Literature Search 
Data base for literature search 
In Ovid: Medline and Old Medline 15.05.2017 
http://gateway.ovid.com/autologin.html 
In EMBASE 15.05.2017 
link: http://www.embase.com/home 
Inclusion criteria: 
 Patients with thyroid dysfunction: subclinical and/or overt hypothyroidism/ 
hyperthyroidism 
 Exposure: at least two categories of thyroid (dys-)function, including a 
euthyroid category 
 Outcome: hemoglobin concentrations and/or proportion of patients 
with/without anemia reported for each of the exposure categories 
Exclusion criteria:  
 Studies exclusively on patients younger than 18 years or on pregnant women 
 Studies exclusively on patients with anemia due to a specific cause (e.g. iron-
deficiency) and co-occurrence of thyroid dysfunction (because in these studies, 
the specific effect of thyroid dysfunction on anemia/hemoglobin cannot be 
disentangled from e.g. iron-deficiency) 
 Case reports/Case series/Reviews (due to lack of comparison group) 
Search strategy MEDLINE/OLD MEDLINE (n= 393) 
Exp thyroid disease/, exp hypothyroidism/, exp hyperthyroidism/, exp thyroid hormones/, 
exp thyrotropin/, (subclinical adj2 (hyperthyr$ or hypothyr$ or dysthyr$ or thyr$)).ti,ab./, 
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exp anemia/, (anem$ or anaem$).ti,ab./, exp cohort studies/, cohort$.tw/, controlled 
clinical trial.pt./, exp epidemiologic methods/ 
Search strategy in Embase (n=2,328) 
thyroid disease/exp, hypothyroidism/exp, hyperthyroidism/exp, thyroid hormones/exp, 
thyrotropin/exp, (subclinical NEAR/2 (hyperthyr* or hypothyr* or dysthyr* or thyr*)):ab,ti, 
anemia/exp, anem*:ab,ti or anaem*:ab,ti, cohort analysis/exp, cohort*:ab,ti, controlled 
clinical trial/exp, epidemiology/exp 
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eTable 1: Multiple linear regression: hemoglobin concentrations [g/dl] compared across 
fT4 quintiles in the cross-sectional study population (N=12,337) 
 
1st fT4 
quintile 
2nd fT4 
quintile 
3rd fT4 
quintile 
4th fT4 
quintile 
5th fT4 
quintile 
Crude analysis 
-0.30 
(-0.38 to -
0.23) 
-0.11 
(-0.19 to -
0.04) 
Ref. 
0.09 
(0.02 to 
0.17) 
0.15 
(0.07 to 
0.22) 
Age- and sex-
adjusted 
analysis 
-0.16 
(-0.22 to -
0.10) 
-0.08 
(-0.14 to -
0.02) 
Ref. 
0.05 
(-0.02 to 
0.11) 
0.02 
(-0.04 to 
0.08) 
Multivariable° 
analysis 
with imputed§ 
data 
-0.16 
(-0.22 to -
0.10) 
-0.08 
(-0.14 to -
0.02) 
Ref. 
0.05 
(-0.01 to 
0.11) 
0.01 
(-0.06 to 
0.07) 
Multivariable° 
analysis  
with original 
data+ 
-0.13 
(-0.20 to -
0.06) 
-0.09 
(-0.16 to -
0.02) 
Ref. 
0.05 
(-0.02 to 
0.11) 
0.03 
(-0.04 to 
0.10) 
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eTable 2: Odds ratio for anemia in the cross-sectional study population (N=12,337) 
 OHypo SHypo Euthyroidism SHyper OHyper 
Anemia N (%) 
29 
(14.97) 
55 (8.54) 866 (7.75) 18 (6.67) 8 (16.00) 
OR for anemia 
(95%CI) 
     
Crude analysis  
2.03
(1.36-
3.02) 
1.11
(0.84-
1.48) 
Ref. 
0.85 
(0.52-
1.38) 
2.27 
(1.06-
4.84) 
Age- and sex-
adjusted analysis  
1.75 
(1.17-
2.62) 
1.00 
(0.75-
1.33) 
Ref. 
0.83 
(0.51-
1.34) 
2.28 
(1.06-
4.90) 
Multivariable° with 
imputed§ data 
1.96
(1.29-
2.98) 
0.93
(0.69-
1.25) 
Ref. 
0.74 
(0.44-
1.23) 
2.18 
(0.98-
4.87) 
Multivariable with 
original data+  
2.00 
(1.17-
3.44) 
0.88 
(0.57-
1.34) 
Ref. 
0.46 
(0.17-
1.21) 
2.13 
(0.62-
7.31) 
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eTable 3: Odds ratio for anemia in the cross-sectional study 
population, using fT4 quintiles as exposure (N=12,337) 
 
1st fT4 
quintile 
2nd fT4 
quintile 
3rd fT4 
quintile 
4th fT4 
quintile 
5th fT4 
quintile 
Anemia N (%) 249 (9.58) 205 (8.60) 187 (7.39) 173 (6.90) 162 (7.00) 
OR for anemia 
(95%CI) 
     
Crude analysis 
1.33 
(1.09-1.62) 
1.18 
(0.96-1.45) 
Ref. 
0.93 
(0.75-1.15) 
0.94 
(0.76-1.17) 
Age- and sex-
adjusted analysis 
1.24 
(1.01-1.51) 
1.16 
(0.94-1.43) 
Ref. 
0.95 
(0.77-1.18) 
1.02 
(0.81-1.26) 
Multivariable° with 
imputed§ data  
1.25 
(1.02-1.54) 
1.18 
(0.95-1.46) 
Ref. 
0.96 
(0.77-1.19) 
1.03 
(0.82-1.29) 
Multivariable with 
original data+ 
1.34 
(0.99-1.80) 
1.42 
(1.05-1.90) 
Ref. 
1.09 
(0.79-1.49) 
1.11 
(0.80-1.53) 
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eTable 4: Hazard ratio for anemia in the prospective study population, using fT4 quintiles 
as exposure (N=7,031)* 
 
1st fT4 
quintile 
2nd fT4 
quintile 
3rd fT4 
quintile 
4th fT4 
quintile 
5th fT4 
quintile 
Anemia N (%) 96 (6.79) 85 (5.96) 111 (7.57) 72 (4.99) 96 (7.49) 
HR for anemia 
(95%CI) 
     
Crude analysis 
0.87 
(0.66-1.15) 
0.74 
(0.56-0.99) 
Ref. 
0.68 
(0.50-0.91) 
0.99 
(0.75-1.30) 
Age- and sex-
adjusted analysis 
0.86 
(0.65-1.13) 
0.75 
(0.56-0.99) 
Ref. 
0.68 
(0.50-0.91) 
1.02 
(0.77-1.34) 
Multivariable° with 
imputed§ data  
0.85 
(0.64-1.11) 
0.75 
(0.56-1.00) 
Ref. 
0.68 
(0.50-0.91) 
1.05 
(0.80-1.38) 
Multivariable° with 
original data+ 
0.80 
(0.59-1.10) 
0.56 
(0.40-0.79) 
Ref. 
0.57 
(0.40-0.82) 
1.09 
(0.80-1.49) 
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Table 5: Description of included studies about thyroid function and anemia 
Author
, year 
Study 
Design 
Study 
population
, n 
Definition 
of thyroid 
dysfunctio
n  
Outcom
e 
Results 
Quality 
assessment/Co
mments 
Lippi G, 
2008(1
) 
Cross-
section
al* 
6,534 
consecutiv
e female 
referrals 
from GPs 
to a 
university 
hospital 
Hypothyroi
dism (TSH 
>2.5mU/l, 
n=1988) 
Euthyroidis
m (TSH 
0.20-
2.5mU/l, 
n=4426) 
Hyperthyroi
dism (TSH 
<0.20mU/l, 
n=120) 
Anemia 
defined 
as 
Hb<12g
/dl 
Hypothyroi
dism: Hb 
132g/l 
(p=0.03), 
prevalence 
of anemia 
15.5% 
(p=0.64) 
Euthyroidis
m (ref. 
group): Hb 
133g/l, 
prevalence 
of anemia 
13.8% 
Hyperthyroi
dism: Hb 
131g/l 
(p=0.04), 
prevalence 
of anemia 
15.8% 
(p=0.58) 
 
- Only females 
- Selected study 
population 
(consecutive 
referrals) 
- Uncommon 
definition of 
hypothyroidis
m (usually TSH 
>4.5 mU/l) and 
hyperthyroidis
m (usually TSH 
<0.5mU/l) 
- No adjustment 
for potential 
confounders 
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is 
pr
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Vitale 
G, 
2010(2
) 
Cross-
section
al* 
316 
hospitalize
d patients 
>65 years 
 
Hypothyroi
dism 
according 
to TSH (no 
clear 
definition 
reported) 
Anemia 
(female 
Hb 
<12g/dl, 
male Hb 
<13g/dl
) 
155 (49%) 
patients 
with 
anemia. 
Prevalence 
of 
hypothyroid
ism 
in anemic 
patients: 
20%  
in non-
anemic 
patients: 
9.9% 
p=0.01 
- Selected study 
population 
(hospitalized 
patients) 
- Definition of 
hypothyroidis
m is not 
reported 
- No adjustment 
for potential 
confounders 
- 9/31 
hypothyroid 
patients were 
selected for 
thyroxine 
treatment and 
Hb improved 
1.6g/dl on 
average 
- It is reported 
that 21 
patients with 
hypothyroidis
m and anemia 
had no other 
reason for 
anemia. It 
remains 
unclear 
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is 
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oo
f. 
why/how only 
9 out of 21 
were selected 
for thyroxine 
treatment. 
Bremn
er AP, 
2012(3
) 
Cross-
section
al, 
populati
on-
based 
cohort 
1,098 
outpatients 
(patients 
with 
hyperthyroi
dism were 
excluded) 
SHypo (TSH 
0.4-
4.0mU/l, 
fT4 9-
23pmol/l, 
n=87) 
Euthyroidis
m defined 
as TSH and 
fT4 both in 
the ref. 
range, 
n=1011 
Hb and 
other 
erythro
cyte 
parame
ters 
SHypo: Hb 
136.9g/l  
Euthyroidis
m: Hb 
141.8g/l 
p=0.29 
- Small 
likelihood of 
selection bias 
- Small number 
of participants 
with SHypo 
- Relevant 
confounders 
considered in 
analysis 
Den 
Elzen 
WPJ, 
2015(4
) 
Cross-
section
al, 
populati
on-
based 
cohort 
526 
outpatients
>85 years 
 
OHypo 
(TSH 
>4.5mU/L, 
fT4 <13 
pmol/l, 
n=40) 
SHypo (TSH 
>4.5mU/L, 
fT4 13-
23pmol/l, 
n=35) 
Euthyroidis
Anemia 
(female 
Hb<12g
/dl, 
male 
Hb<13 
g/dl) 
OHypo: Hb 
12.8g/dl 
(p=0.37), 
prevalence 
of anemia 
35% (OR 
1.76, 95% CI 
0.89-3.51) 
SHypo: Hb 
13.1g/dl 
(p=0.68), 
prevalence 
- Small 
likelihood of 
selection bias 
- Small number 
of participants 
with OHypo 
and SHypo 
- Not reported 
that patients 
with 
hyperthyroidis
m were 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ité
 d
e 
La
us
an
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
11
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 41 of 67 
 
 
 
41 
Th
yr
oi
d 
Th
yr
oi
d 
Dy
sf
un
ct
io
n 
an
d 
An
em
ia
: A
 P
ro
sp
ec
tiv
e 
Co
ho
rt
 S
tu
dy
 a
nd
 a
 S
ys
te
m
at
ic 
Re
vi
ew
 (D
OI
: 1
0.
10
89
/t
hy
.2
01
7.
04
80
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
m (TSH 0.5-
4.5mU/l, 
n=451) 
of anemia 
26% (OR 
1.16, 95% CI 
0.52-2.57) 
Euthyroidis
m (ref. 
group): Hb 
13.0g/dl, 
prevalence 
of anemia 
25% 
probably 
excluded 
- Analyses only 
adjusted for 
sex, other 
potential 
confounders 
not mentioned 
Jafarza
deh A, 
2010(5
) 
Case-
control 
Patients 
admitted 
to a 
hospital: 
50 women 
with 
OHypo 
50 women 
with 
OHyper 
50 sex-and 
age-
matched 
euthyroid 
controls 
OHypo (TSH 
>3.5mIU/l, 
fT3 
<1.6nmol/l, 
fT4 
<60nmol/l) 
Euthyroidis
m defined 
as TSH and 
fT4/3 in ref. 
range 
OHyper 
(TSH 
<0.35mIU/l, 
fT3 
>3.6nmol/l, 
fT4 
>160nmol/l
) 
Hb and 
other 
erythro
cyte 
parame
ters 
OHypo: Hb 
13.2g/dl 
(p=0.01) 
Euthyroidis
m: Hb 
14.0g/dl 
(ref.) 
OHyper: Hb 
13.8g/dl 
(p=not 
significant) 
- Unclear how 
participants 
with thyroid 
dysfunction 
were selected 
and if they 
were 
representative 
of all potential 
patients with 
thyroid 
dysfunction 
- Unclear how 
controls were 
selected 
(except for 
age- and sex-
matching) 
- Uncommon 
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 d
iff
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is 
pr
oo
f. 
TSH ref. range 
(0.35 – 3.6 
mU/l) 
- No adjustment 
for potential 
confounders 
(except for 
age- and sex-
matching) 
- Patients 
suffered from 
severe OHypo 
and OHyper 
(mean TSH 
136.5mU/l and 
0.06mU/l, 
respectively) 
Erdoga
n M, 
2012(6
) 
Case-
control 
Participant
s were 
selected 
from 4,800 
patients 
who 
presented 
for the first 
time at the 
endocrinol
ogy 
departmen
t of a 
OHypo 
(TSH 
>4.2mU/l, 
fT4 
<0.70ng/dl) 
SHypo (TSH 
>4.2mU/l, 
fT4 in ref. 
range) 
Euthyroid 
(TSH 0.27-
4.2mU/l, 
fT4 0.70 
Anemia 
(female 
Hb<12g
/dl, 
male 
Hb< 
13g/dl) 
OHypo: Hb 
11.9g/dl, 
prevalence 
of anemia 
43%  
SHypo: Hb 
12.4g/dl, 
prevalence 
of anemia 
39%  
Euthyroidis
m: Hb 
12.8g/dl, 
- Although the 
derivation of 
the study 
population is 
well reported, 
it is 
astonishing 
that the 
numbers come 
down to round 
figures (100, 
100, 200), 
leaving the 
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oo
f. 
university 
hospital: 
100 OHypo 
100 SHypo 
200 
healthy, 
euthyroid 
controls 
1.48ng/dl) prevalence 
of anemia 
26% 
Compared 
to 
euthyroidis
m, all 
results are 
statistically 
significant 
potential for 
selection bias 
- No community 
controls 
(persons 
attending 
outpatient 
clinic) 
- No adjustment 
for potential 
confounders 
- Patients 
suffered from 
severe OHypo 
and SHypo 
(mean TSH 
43.1mU/l and 
13.9mU/l, 
respectively) 
Bashir 
H, 
2012(7
)  
Case-
control 
Participant
s were 
referred to 
the 
endocrinol
ogy 
departmen
t of a 
university 
hospital: 
100 
OHypo 
(TSH 
>4.3mU/l, 
fT4 below 
ref. range) 
SHypo (TSH 
>4.3mU/l, 
normal fT4) 
Hb and 
other 
erythro
cyte 
parame
ters 
Untreated 
OHypo: Hb 
10.7g/dl  
Treated 
OHypo: Hb 
12.6g/dl  
Untreated 
SHypo: Hb 
10.8g/dl 
Treated 
SHypo: Hb 
- Unclear how 
the study 
population 
was derived 
- No community 
controls 
(persons 
attending 
outpatient 
clinic) 
- No adjustment 
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pr
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f. 
untreated 
OHypo  
100 treated 
OHypo 
110 
untreated 
SHypo 
110 treated 
SHypo 
180 age- 
and sex-
matched 
euthyroid 
controls 
12.0g/dl 
Euthyroidis
m: Hb 
14.7g/dl 
for potential 
confounders 
Srikrish
na R, 
2015(8
) 
Case-
control 
Participant
s were 
randomly 
selected 
from 
patients 
attending 
an 
outpatient 
university 
hospital: 
108 OHypo 
123 SHypo 
209 age-
and sex-
matched 
OHypo 
(TSH above 
and fT4 
below ref. 
range) 
SHypo (TSH 
above and 
fT4 within 
ref. range) 
Euthyroids 
(TSH and 
fT4 in ref. 
range) 
Anemia 
(female 
Hb<12g
/dl, 
male 
Hb< 
13g/dl) 
OHypo: Hb 
11.3g/dl 
(p<0.001), 
prevalence 
of anemia 
49.3% 
(p<0.001) 
SHypo: Hb 
12.7g/dl 
(p<0.001), 
prevalence 
of anemia 
46.8% 
(p=0.018) 
Euthyroidis
m (ref. 
- Unclear how 
cases were 
“randomly” 
selected 
- No community 
controls 
(persons 
attending 
outpatient 
clinic) 
- No ref. ranges 
of thyroid 
hormones 
- No adjustment 
for potential 
confounders 
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is 
pr
oo
f. 
healthy, 
euthyroid 
controls 
group): Hb 
13.3g/dl, 
prevalence 
of anemia 
28% 
- Patients 
suffered from 
severe OHypo 
and SHypo 
(mean TSH 
57.0mU/l and 
11.4mU/l, 
respectively) 
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eTable 6: Description of excluded studies about thyroid function and anemia 
Author, 
year 
Study 
Design 
Study 
population
, n 
Definition 
of thyroid 
dysfunctio
n  
Outcome Results Comments 
Christ-
Crain M, 
2003(9) 
RCT 66 women 
TSH 
reference 
range  
0.3-4mU/l 
Not 
clearly 
defined 
LT4 
treatment in 
SCH results 
in increased 
erythropoie
tin levels 
Excluded 
because no 
euthyroid 
control 
group 
Cinemre H, 
2009(10) 
RCT 
51 
Consecutiv
e 
outpatient
s 
SHypo: 
Elevated 
TSH in the 
setting of 
normal 
total or 
free fT4 
and fT3 
Clinical 
satisfacto
ry 
Increase 
in Hb 
Hb 
increased by 
0.4 g/dl in 
the iron 
treatment 
group [95% 
confidence 
interval (CI) 
0.2-0.7], by 
1.9g/dl in 
the 
iron/levothy
roxine 
treatment 
group [95% 
CI 1.5-2.3] 
RCT in 
patients with 
SHypo and 
iron-
deficiency 
anemia 
examining 
the effect of 
iron 
substitution 
with and 
without 
Levothyroxin
e. Excluded 
because the 
main cause 
of anemia is 
iron 
deficiency 
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 b
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 p
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 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
and the 
contribution 
of SHypo to 
the 
development 
of anemia 
cannot be 
discerned 
Mohamma
dreza R, 
2013(11) 
RCT 60 
SHypo 
defined as 
TSH 4.5-
10mU/l 
and 
normal fT3 
and fT4 
Iron 
deficiency 
Anemia 
Change 
from BL 
in Hb, 
ferritin 
and TSH 
A 
combination 
of iron salt 
and 
levothyroxin
e is better 
than each 
alone 
RCT in 
patients with 
SHypo and 
iron-
deficiency 
anemia 
examining 
the effect of 
iron 
substitution 
with and 
without 
Levothyroxin
e. Excluded 
because the 
main cause 
of anemia is 
iron 
deficiency 
and the 
contribution 
of SHypo to 
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 d
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oo
f. 
the 
development 
of anemia 
cannot be 
discerned 
Choi CW, 
2005(12) 
Prospec
tive 
study 
332 
outpatient
s 
No 
assessmen
t of thyroid 
dysfunctio
n at BL 
Incidence 
of 
Anemia 
(Hb<12g/
dl, Hb< 
13g/dl) 
24 (7.2%) 
incident 
anemia 
cases during 
3y of FUP, 1 
subject with 
hypothyroid
ism 
TSH only 
assessed in 
incident 
anemia cases 
(no TSH 
assessment 
in non-
anemic 
group) 
Gianoukaki
s AG, 
2009(13) 
Prospec
tive 
Study 
98 
Consecutiv
e 
outpatient
s 
OHyper 
due to 
Grave’s 
disease 
Anemia 
(Hb 
referenc
e range 
females 
11.9-
14.9g/dl, 
men 
13.9-
16.9g/dl) 
31 
participants 
had anemia, 
mean Hb 
11.3g/dl 
Limited to 
patients with 
Graves’ 
disease (no 
control 
group) 
Joosten E, 
2015(14) 
Prospec
tive 
study 
191 
Consecutiv
e 
hospitalize
d older 
patients 
- 
Iron 
deficienc
y 
anemia, 
Anemia 
of 
Of 56 
patients 
with iron 
deficiency 
anemia 3 
had thyroid 
Only patient 
with iron-
deficiency 
and anemia 
of chronic 
disease 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ité
 d
e 
La
us
an
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
11
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 49 of 67 
 
 
 
49 
Th
yr
oi
d 
Th
yr
oi
d 
Dy
sf
un
ct
io
n 
an
d 
An
em
ia
: A
 P
ro
sp
ec
tiv
e 
Co
ho
rt
 S
tu
dy
 a
nd
 a
 S
ys
te
m
at
ic 
Re
vi
ew
 (D
OI
: 1
0.
10
89
/t
hy
.2
01
7.
04
80
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
chronic 
disease 
dysfunction, 
of 135 
patients 
with anemia 
of chronic 
disease had 
thyroid 
dysfunction 
Bahemuka 
M, 
1975(15) 
Cross- 
section
al 
2000 
>60 y 
inpatients 
Hypothyroi
dism 
according 
to TSH (no 
clear 
definition 
reported) 
- 
46 (2.3%) 
were 
hypothyroid 
7 had 
pernicious 
anemia, no 
other 
results on 
anemia 
reported 
Anemia due 
to 
autoimmune 
disorder 
(pernicious 
anemia). 
Excluded due 
to lacking 
information 
on 
hematologic
al 
parameters/
anemia in 
euthyroid 
comparison 
group 
Carmel R, 
1982(16) 
Cross-
section
al 
162 with 
pernicious 
anemia 
TSH 
according 
1982 
Not 
clearly 
defined 
High 
prevalence 
of 
pernicious 
anemia in 
Excluded 
because only 
on patients 
with 
pernicious 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ité
 d
e 
La
us
an
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
11
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 50 of 67 
 
 
 
50 
Th
yr
oi
d 
Th
yr
oi
d 
Dy
sf
un
ct
io
n 
an
d 
An
em
ia
: A
 P
ro
sp
ec
tiv
e 
Co
ho
rt
 S
tu
dy
 a
nd
 a
 S
ys
te
m
at
ic 
Re
vi
ew
 (D
OI
: 1
0.
10
89
/t
hy
.2
01
7.
04
80
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
OHyper 
(8.6%) and 
OHypo 
(11.7%) 
anemia 
Völzke H, 
2006(17) 
Cross-
section
al 
4111  
outpatient
s 
TSH and 
fT4 and/or 
fT3 tertiles 
Ferritin 
serum 
levels 
No 
association 
between 
thyroid 
function 
and serum 
ferritin 
levels 
Excluded 
because no 
assessment 
of anemia 
Omar S, 
2010(18) 
(French 
article) 
Cross-
section
al 
Hyperthyr
oidism 235 
Hypothyroi
dism 177 
Hyperthyr
oidism TSH 
<0.10mUl/l
Hypothyroi
dism TSH 
>5.0mUl/l 
Anemia 
(female 
Hb 
<12g/dl, 
male Hb 
<13g/dl) 
Prevalence 
of anemia 
40.9% in 
hyperthyroi
dism, 
prevalence 
of anemia 
57.1% in 
hypothyroid
ism  
Excluded 
because no 
euthyroid 
control 
group 
Schindhel
m RK, 
2012(19) 
Cross-
section
al 
762 
TSH, only 
euthyroid 
Erythrocy
te indices
Free T4, but 
not TSH is 
associated 
with 
erythrocyte 
indices 
(positive 
association 
Excluded 
because only 
euthyroid 
subjects 
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with Hb, 
erythrocyte 
count and 
hematocrit) 
Petrosyan 
I, 
2012(20) 
Cross-
section
al 
95 patients 
>/= 65 y 
with 
anemia 
- 
Cause of 
anemia 
2 of 360 
participants 
(2.1%) had 
hypothyroid
ism 
Excluded 
because no 
non-anemic 
control 
group and no 
assessment 
of thyroid 
function 
Lopez-
Berastegui 
O, 
2013(21) 
Cross-
Section
al 
581 
65 y or 
alder 
TSH 
>10mIU/l 
Anemia 
(female 
Hb 
<12g/dl, 
male Hb 
<13g/dl) 
- 
Relevant 
information 
on thyroid 
function and 
anemia 
lacking 
Velarde-
Mayol C, 
2015(22) 
(Spanish 
article) 
Cross 
section
al 
5,082 
Consecutiv
e 
outpatient
s 
Autoimmu
ne thyroid 
disease 
without 
further 
definition 
Perniciou
s anemia  
Prevalence 
of Thyroid 
autoimmun
e disease 
8.2%, 
prevalence 
of 
pernicious 
anemia 
3.3% 
Only on 
autoimmune 
thyroid 
diseases  
M’Rhabet-
Bensalah 
Cross-
section
- - - - 
Same study 
as M’Rhabet-
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oo
f. 
K, 
2015(23) 
al 
(confer
ence 
abstrac
t) 
Bensalah K, 
Clinical 
Endocrinolog
y 2016 
M’Rhabet-
Bensalah 
K, 
2015(23) 
Cross-
section
al 
- - - - 
Same study 
as M’Rhabet-
Bensalah K, 
Clinical 
Endocrinolog
y 2016 
M’Rhabet-
Bensalah 
K, 
2016(23) 
Cross-
section
al 
8971 
population
-based 
participant
s 
Thyroid 
dysfunctio
n 
According 
TSH 
Anemia 
(female 
Hb 
<12g/dl, 
male Hb 
<13g/dl) 
The 
prevalence 
of anemia 
was higher 
in OHyper 
(14.6%) but 
not 
increased in 
SHypo/SHyp
er 
Same study 
population 
as present 
study 
Ottesen 
M, 
1995(24) 
Case 
Control 
35 patients 
with 
pernicious 
anemia 
22 healthy 
controls 
Cobalamin 
Treatment 
Thyroid 
function 
and 
autoimm
unity 
No effect of 
cobalamin 
treatment 
on thyroid 
function 
Cases were 
patients with 
decreased 
plasma 
cobalamin, 
and anemia 
was not the 
outcome 
Kosenli A, Case - - - - Same study 
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2009(25) Control 
Study 
(confer
ence 
abstrac
t) 
as Erdogan 
M, Endocrine 
Journal 2012 
Price EA, 
2011(26) 
Case-
control 
190 older 
outpatient
s (>65y) 
referrals to 
hematolog
y 
Non 
anemic 
controls 
(n=not 
specified) 
According 
to TSH 
Anemia 
(Hb<12g/
dl, Hb< 
13g/dl), 
Cause of 
anemia 
No subject 
was found 
to have 
anemia 
related to 
thyroid 
dysfunction 
No 
information 
about 
thyroid 
function of 
the control 
group -> 
excluded 
(none of 190 
anemic 
patients had 
thyroid 
dysfunction) 
Dorgalaleh 
A, 
2013(27) 
Case 
Control  
102 
patients 
with 
OHypo, 84 
with 
OHyper, 
118 
healthy 
controls 
OHypo 
(TSH 
>5.5mU/l ) 
OHyper 
(TSH 
<0.3mU/l) 
Blood 
cell 
count/ 
red 
blood 
cell 
indices 
Statistically 
relevant 
difference in 
RBC, MCH, 
MCHC, RDW 
and HCT 
Pediatric 
population 
Aktas G, 
2014(28) 
Case 
Control 
102 
patients 
Hashimoto 
Thyroiditis 
RDW 
Patients 
with 
Anemia was 
an exclusion 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ité
 d
e 
La
us
an
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
11
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 54 of 67 
 
 
 
54 
Th
yr
oi
d 
Th
yr
oi
d 
Dy
sf
un
ct
io
n 
an
d 
An
em
ia
: A
 P
ro
sp
ec
tiv
e 
Co
ho
rt
 S
tu
dy
 a
nd
 a
 S
ys
te
m
at
ic 
Re
vi
ew
 (D
OI
: 1
0.
10
89
/t
hy
.2
01
7.
04
80
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
with HT 
63 healthy 
controls 
elevated 
RWD should 
be further 
evaluated 
for HT 
criterion 
Thudhope 
GR, 
1960(29) 
Case 
series 
166 
Hypothyroi
dism 
according 
to 
standard in 
1960 
Prevalen
ce of 
anemia 
(female 
Hb 
<12g/dl, 
male Hb 
<13 g/dl) 
10% iron 
deficiency 
anemia 
7.8% 
pernicious 
anemia 
Excluded 
because lack 
of control 
group 
Rivlin RS, 
1969(30) 
Case 
series 
9 
According 
standard in 
1969 
Iron 
utilizatio
n 
There might 
be an 
impairment 
in the iron 
utilization of 
hyperthyroi
d patients 
developing 
anemia 
Excluded 
because lack 
of control 
group 
Horton L, 
1975(31) 
Case 
series 
202 
OHypo 
according 
to 
standard in 
1975 
Anemia 
(female 
Hb 
<12g/dl, 
male Hb 
<13 g/dl) 
Anemia was 
present in 
39 of 172 
women and 
14 of 30 
men 
Excluded 
because lack 
of control 
group 
Das KC, 
1975(32) 
Case 
series 
44 
Not clearly 
defined 
Not 
clearly 
Stimulation 
of 
Excluded 
because no 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ité
 d
e 
La
us
an
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
11
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 55 of 67 
 
 
 
55 
Th
yr
oi
d 
Th
yr
oi
d 
Dy
sf
un
ct
io
n 
an
d 
An
em
ia
: A
 P
ro
sp
ec
tiv
e 
Co
ho
rt
 S
tu
dy
 a
nd
 a
 S
ys
te
m
at
ic 
Re
vi
ew
 (D
OI
: 1
0.
10
89
/t
hy
.2
01
7.
04
80
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
defined erythropoie
sis by 
thyroid 
hormones 
seems to be 
erythropoie
tin 
mediated 
euthyroid 
control 
group 
Nightingal
e S, 
1977(33) 
Case 
series 
239 
OHyper 
according 
to 
standard in 
1977 
Anemia 
(female 
Hb 
<12g/dl, 
male Hb 
<13 g/dl) 
Anemia was 
present in 
37 of 207 
women and 
9 of 39 men 
Excluded 
because lack 
of control 
group 
Sims EG, 
1983(34) 
Case 
Report 
- 
Not 
specified 
Not 
specified 
- 
Excluded 
because lack 
of control 
group 
Bertola G, 
1998(35) 
(Italian 
article) 
Case 
Report 
- 
OHyper in 
Basedow 
TSH 
<0.3mU/l, 
fT4 5ng/l 
Pancytop
enia 
Normalizati
on of 
hematologic
al 
parameters 
after 
treatment 
of 
hyperthyroi
dism 
Excluded 
because lack 
of control 
group 
Dharmaraj
an MD, 
Case 
Report 
- 
No clear 
definition 
Anemia 
(female 
- 
Excluded 
because lack 
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2004(36) Hb 
<12g/dl, 
male Hb 
<13g/dl) 
of control 
group 
Fein HG, 
1975(37) 
Review - 
Not clearly 
defined 
- - 
Excluded 
because it’s a 
review 
Ford HC, 
1988(38) 
Review - 
OHyper 
Not clear 
defined 
Ery-/Ery-
indices 
- 
Excluded 
because it’s a 
review 
Antonijevi
c N, 
1999(39) 
(Croatian 
article) 
Review - - - - 
Excluded 
because it’s a 
review 
Levy C, 
2007(40) 
(French 
article) 
Review - - - - 
Excluded 
because it’s a 
review 
Kaferle J, 
2009(41) 
Review - - 
Macrocyt
osis 
Non-
alcoholic 
liver disease 
and 
hypothyroid
ism account 
for a 
substantial 
proportion 
of 
macrocytosi
Excluded 
because it’s a 
review 
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s 
Stein SA, 
2010(42) 
Review - - - - 
Excluded 
because it’s a 
review 
Hennessey 
JV(43), 
2015 
Review - SHypo 
Iron-
deficienc
y anemia 
Anemia is 
significantly 
more 
common in 
OHypo/SHy
po 
Excluded 
because it’s a 
review 
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Table 7: Newcastle-Ottawa Quality Assessment Scale Cross-Sectional Studies 
 
Study Selection 
Comparab
ility 
Outcome Sco
re 
 
Representative
ness 
of the sample 
Non-
respond
ers 
Ascertainm
ent of 
exposure 
Confoundi
ng 
Factors 
are 
controlled 
Assessm
ent of 
outcome 
Statisti
cal Test 
Lippi 
G, 
2008(
1) 
Selected Group 
No 
descripti
on 
Validated 
measurem
ent tool (1 
point) 
No 
Record 
linkage 
(1 point) 
Clearly 
describ
ed 
(1 
point) 
3 of 
max
. 7 
Vitale 
G, 
2010(
2) 
Selected Group 
No 
descripti
on 
Validated 
measurem
ent tool (1 
point) 
No 
 
Record 
linkage 
(1 point) 
Clearly 
describ
ed 
(1 
point) 
3  
of 
max
. 7 
Bremn
er AP, 
2012(
3) 
Truly 
representative 
of the average 
in the target 
population (1 
point) 
No 
descripti
on 
Validated 
measurem
ent tool (1 
point) 
Yes (1 
point) 
Record 
linkage 
(1 point) 
Clearly 
describ
ed 
(1 
point) 
5  
of 
max
. 7 
Den 
Elzen 
WPJ, 
2015(
4) 
Truly 
representative 
of the average 
in the target 
population (1 
point) 
No 
descripti
on 
Validated 
measurem
ent tool (1 
point) 
Yes (1 
point) 
Record 
linkage 
(1 point) 
Clearly 
describ
ed 
(1 
point) 
5  
of 
max
. 7 
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eTable 8: Newcastle-Ottawa Quality Assessment Scale Case-Control Studies 
Study Selection  Compar
ability 
Exposure Sc
or
e 
 
Case 
defini
tion 
Represent
ativeness 
of the 
case 
Select
ion of 
contr
ols 
Defini
tion 
of 
contr
ols 
Compar
ability 
of the 
cases 
and 
control
s 
Ascertai
nment 
of 
exposur
e 
 
Same 
method 
of 
ascertai
nment 
for 
cases 
and 
controls 
Non-
Respo
nse 
Rate 
Jafarz
adeh 
A, 
2010(
5) 
Recor
d 
linkag
e 
Potential 
for 
selection 
bias 
No 
descri
ption 
No 
descri
ption 
No 
adjustm
ent for 
potenti
al 
confou
nding 
Secure 
record 
(1 
point) 
Yes 
(1 
point) 
No 
design
ation 
2 
of 
m
ax
. 
10 
Erdog
an M, 
2012(
44) 
Recor
d 
linkag
e 
Potential 
for 
selection 
bias 
Hospit
al 
contro
ls 
No 
descri
ption 
No 
adjustm
ent for 
potenti
al 
confou
nding 
Secure 
record 
(1 
point) 
Yes 
(1 
point) 
No 
design
ation 
2 
of 
m
ax
. 
10 
Bashir 
H, 
2012(
Recor
d 
linkag
Potential 
for 
selection 
Hospit
al 
contro
No 
descri
ption 
No 
adjustm
ent for 
Secure 
record 
(1 
Yes 
(1 
point) 
No 
design
ation 
2 
of 
m
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7) e bias ls potenti
al 
confou
nding 
point) ax
. 
10 
Srikr
ishn
a R, 
201
5(8) 
Reco
rd 
linka
ge 
Potential 
for 
selection 
bias 
Hospit
al 
contro
ls 
No 
descri
ption 
No 
adjust
ment 
for 
potenti
al 
confou
nding 
Secure 
record 
(1 
point) 
Yes 
(1 
point) 
No 
design
ation 
2 of 
max. 
10 
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eTable 1: In brackets are 95% confidence intervals 
°Adjustments: age, sex, BMI, smoking status, myocardial infarction, diabetes mellitus, 
stroke, ferritin, eGFR, CRP, MCV 
§Imputation for BMI (24 [0.19%] missing), smoking status (93 [0.75%] missing), ferritin 
(3,851 [31.2%] missing), eGFR (3,266 [26.5%] missing), and CRP (3,311 [26.8%] missing), 
complete data for age- and sex-adjusted analysis 
+N = 8,275 
Abbreviations: fT4, free thyroxine; N, number; Ref., reference; BMI, body mass index; eGFR, 
estimated glomerular filtration rate; CRP, C-reactive protein; MCV, mean corpuscular 
volume  
eTable 2: In brackets are 95% confidence intervals, if not stated otherwise 
°Adjustments: age, sex, BMI, smoking status, myocardial infarction, ferritin, eGFR, CRP, MCV 
§ Imputation for BMI (24 [0.19%] missing), smoking status (93 [0.75%] missing), ferritin 
(3,851 [31.2%] missing), eGFR (3,266 [26.5%] missing), and CRP (3,311 [26.8%] missing), 
complete data for age- and sex-adjusted analysis 
+N = 8,275  
Abbreviations: N, number; OHypo, overt hypothyroidism; SHypo, subclinical 
hypothyroidism; SHyper, subclinical hyperthyroidism; OHyper, overt hyperthyroidism; OR, 
odds ratio; CI, confidence interval; Ref., reference; BMI, body mass index; eGFR, estimated 
glomerular filtration rate; CRP, C-reactive protein; MCV, mean corpuscular volume  
eTable 3: In brackets are 95% confidence intervals, if not stated otherwise  
°Adjustments: age, sex, BMI, smoking status, myocardial infarction, ferritin, eGFR, CRP, MCV 
§ Imputation for BMI (24 [0.19%] missing), smoking status (93 [0.75%] missing), ferritin 
(3,851 [31.2%] missing), eGFR (3,266 [26.5%] missing), and CRP (3,311 [26.8%] missing), 
complete data for age- and sex-adjusted analysis 
+N = 8,275 
Abbreviations: fT4, free thyroxine; N, number; OR, odds ratio; CI, confidence interval; Ref., 
reference; BMI, body mass index; eGFR, estimated glomerular filtration rate; CRP, C-reactive 
protein; MCV, mean corpuscular volume  
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eTable 4: In brackets are 95% confidence intervals, if not stated otherwise  
*We included only participants without anemia or overt thyroid dysfunction at 
baseline, and with available hemoglobin assessment during follow-up 
°Adjustments: age, sex, BMI, diabetes mellitus, ferritin, MCV  
§Imputation for BMI (11 [0.16%] missing), smoking status (44 [0.63%] missing), ferritin 
(2,068 [29.4%] missing), eGFR (1,835 [26.1%] missing), and CRP (1,855 [26.4%] missing), 
complete data for age- and sex-adjusted analysis  
+N = 4,955  
Abbreviations: fT4, free thyroxine; N, number; HR, Hazard ratio; Ref., reference; BMI, body 
mass index; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; MCV, mean 
corpuscular volume  
eTable 5: Abbreviations: CI, confidence interval; fT3, free triiodothyronine; fT4, free 
thyroxine; Hb, hemoglobin; LT4, levothyroxine; n, number; ng, nanogramm; OHyper, overt 
hyperthyroidism; OHypo, overt hypothyroidism; OR, odds ratio; pmol, picomol; SHyper, 
subclinical hyperthyroidism; SHypo, subclinical hypothyroidism; TSH, thyroid stimulating 
hormone; y, year. 
*cross-sectional in terms of assessment of exposure (thyroid hormones) and 
outcome (hemoglobin/anemia) at the same time. 
eTable 6: Abbreviations: CI, confidence Interval; Ery, erythrocyte; Ery-Indices, erythrocyte-
indices; fT3, free triiodothyronine; fT4, free thyroxin; Hb, hemoglobin; HT, Hashimoto 
thyroiditis; n, number; ng, nanogramm; OHyper, overt hyperthyroidism; OHypo, overt 
hypothyroidism; SHyper, subclinical hyperthyroidism; SHypo, subclinical hypothyroidism; 
TSH, Thyroid Stimulating Hormone; RCT, randomized controlled trial; RDW, red blood cell 
distribution width; y, year. 
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eFigure 1: Flow diagram of the systematic review  
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MOOSE Checklist for Meta-analyses of Observational Studies 
General comment on this checklist: We would like to highlight that we primarily report 
results from a cohort study, and only additionally performed a systematic review (without 
meta-analysis) of the literature to interpret the results of our cohort study in the light of 
the whole body of evidence on the topic. Therefore, as our manuscript reports results 
from a cohort study and a systematic review without meta-analysis, it is not exactly 
structured and as detailed as if it only reported results from a systematic review including 
a meta-analysis. 
Item No Recommendation 
Reported 
on Page 
No 
Reporting of background should include 
1 Problem definition 3 
2 Hypothesis statement 3
3 Description of study outcome(s) 3 
4 Type of exposure or intervention used na 
5 Type of study designs used 3 
6 Study population 3 
Reporting of search strategy should include 
7 Qualifications of searchers (eg, librarians and investigators) 3
8 
Search strategy, including time period included in the synthesis 
and key words 
3 
9 
Effort to include all available studies, including contact with 
authors 
na 
10 Databases and registries searched 3
11 
Search software used, name and version, including special features 
used (eg, explosion) 
na 
12 Use of hand searching (eg, reference lists of obtained articles) 3 
13 List of citations located and those excluded, including justification 
App° page 
8  
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14 
Method of addressing articles published in languages other than 
English 
na 
15 Method of handling abstracts and unpublished studies na 
16 Description of any contact with authors na 
Reporting of methods should include 
17 
Description of relevance or appropriateness of studies assembled 
for assessing the hypothesis to be tested 
3 
18 
Rationale for the selection and coding of data (eg, sound clinical 
principles or convenience) 
na* 
19 
Documentation of how data were classified and coded (eg, 
multiple raters, blinding and interrater reliability) 
na* 
20 
Assessment of confounding (eg, comparability of cases and 
controls in studies where appropriate) 
App° 
pages 13 
and 14 
21 
Assessment of study quality, including blinding of quality assessors, 
stratification or regression on possible predictors of study results 
App° 
pages 13 
and 14 
22 Assessment of heterogeneity na* 
23 
Description of statistical methods (eg, complete description of 
fixed or random effects models, justification of whether the 
chosen models account for predictors of study results, dose-
response models, or cumulative meta-analysis) in sufficient detail 
to be replicated 
na* 
24 Provision of appropriate tables and graphics na* 
Reporting of results should include 
25 
Graphic summarizing individual study estimates and overall 
estimate 
na* 
26 Table giving descriptive information for each study included 
App° page 
5 
27 Results of sensitivity testing (eg, subgroup analysis) na* 
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28 Indication of statistical uncertainty of findings na* 
Reporting of discussion should include
29 Quantitative assessment of bias (eg, publication bias) na* 
30 
Justification for exclusion (eg, exclusion of non-English language 
citations) 
na 
31 Assessment of quality of included studies 6-7
Reporting of conclusions should include 
32 Consideration of alternative explanations for observed results 
We only 
drew 
conclusions 
about our 
cohort 
study, not 
about the 
systematic 
review 
33 
Generalization of the conclusions (ie, appropriate for the data 
presented and within the domain of the literature review) 
We only 
drew 
conclusions 
about our 
cohort 
study, not 
about the 
systematic 
review 
34 Guidelines for future research 
We only 
drew 
conclusions 
about our 
cohort 
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Checklist from: Stroup DF, Berlin JA, Morton SC, et al, for the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of Observational 
Studies in Epidemiology. A Proposal for Reporting. JAMA. 2000;283(15):2008-2012. doi: 
10.1001/jama.283.15.2008. 
Transcribed from the original paper within the NEUROSURGERY® Editorial Office, Atlanta, 
GA, United Sates. August 2012. 
°App, Appendix 
* as we performed no meta-analysis, we did not  
study, not 
about the 
systematic 
review 
35 Disclosure of funding source 2 
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